ATRIUM THERAPEUTICS INC (RNA:NASDAQ)
$12.38 -0.05 (-0.4023%)
Analysed ATRIUM THERAPEUTICS INC (RNA:NASDAQ) News Sources
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
27-02-2026
yahoo.com
Sector Update: Health Care Stocks Advance Late Afternoon
16-03-2026
yahoo.com
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
17-03-2026
yahoo.com
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
19-03-2026
pharmavoice.com
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
19-03-2026
yahoo.com
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
20-03-2026
wsj.com
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21-04-2026
yahoo.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
23-04-2026
yahoo.com
Atrium Therapeutics Reports First Quarter 2026 Financial Results
14-05-2026
yahoo.com
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
28-05-2026
yahoo.com
What is the current price of ATRIUM THERAPEUTICS INC (RNA:NASDAQ)?
The current price of ATRIUM THERAPEUTICS INC (RNA:NASDAQ) is $12.38.
ATRIUM THERAPEUTICS INC (RNA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATRIUM THERAPEUTICS INC (RNA:NASDAQ) since the previous trading day is $-0.05.
ATRIUM THERAPEUTICS INC (RNA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATRIUM THERAPEUTICS INC (RNA:NASDAQ) since the previous trading day is -0.4023%.
What is the most recent average sentiment score for ATRIUM THERAPEUTICS INC (RNA:NASDAQ)?
The most recent average sentiment score for ATRIUM THERAPEUTICS INC (RNA:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for ATRIUM THERAPEUTICS INC (RNA:NASDAQ)?
The most recent sentiment for ATRIUM THERAPEUTICS INC (RNA:NASDAQ) is .
SEC-8K** Filing Available For ATRIUM THERAPEUTICS INC (RNA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.